Hypogonadism, Male, Kidney Disease, Chronic
Conditions
Keywords
testosterone, CKD
Brief summary
This study in being conducted in men who have low testosterone and chronic kidney disease. The investigators will evaluate the effects of an oral testosterone preparation, JATENZO, on testosterone levels and hemoglobin (red blood cells).
Detailed description
* Purpose. The purpose of this research is to find out if JATENZO will help increase testosterone levels in men with hypogonadism and chronic kidney disease, determine if there is any improvement in testosterone levels, hemoglobin (red blood cells), muscle strength, lean mass and sexual function. * The dug will be daily for 6 months. Study Procedures. Every 2-4 weeks, the study participant will come in person for a research visit. Investigators will collect a blood sample at certain visits, do a brief physical exam, and obtain vital signs such as height, weight, blood pressure. The study also involves completing questionnaires, measuring body composition by a scan and testing muscle strength. The dose of JATENZO may be adjusted based on the testosterone levels.
Interventions
DRUGJatenzo Pill
oral tablet daily
Sponsors
St. Louis University
Clarus Therapeutics, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
All subjects will receive treatment with JATENZO
Eligibility
Sex/Gender
MALE
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Men between ages of 18-85 years of age * eGFR 15-45 ml/min/1.73m2 by MDRD (Modification of Diet in Renal Disease) equation * Subnormal total serum T concentrations (\<300 ng/dl) on two separate occasions in morning * Symptoms of hypogonadism (as per Endocrine Society guidelines): low libido, erectile dysfunction, fatigue, irritability, depressed mood, poor concentration, increased body fat, decreased muscle bulk, reduced physical performance, sleep disturbance, loss of body hair (15) * Normal iron stores as defined by serum ferritin ≥100 ng/mL and transferrin saturation (TSAT) ≥20%.
Exclusion criteria
* Use of TRT currently or in the past 6 months, including use of over-the-counter androgen containing health supplements (e.g., DHEA) * Hematocrit \>48% (as per Endocrine Society guidelines)(15) * Treatment with erythropoiesis stimulating agents (ESA) * Uncontrolled blood pressure (\>180/100 mm Hg) * Heart Failure, class III or IV * Myocardial infarction, stroke, or heart surgery in the past 3 months * Breast cancer * History of prostate cancer * Prostate specific antigen (PSA) \>4 ng/ml, unless prostate cancer has been ruled out by a urologist (documented in physician notes) * HIV or untreated hepatitis C * Untreated, severe obstructive sleep apnea * Initiated iron replacement in the last 3 months * deep venous thrombosis or pulmonary embolism in the last 3 months * recurrent (more than once) deep venous thrombosis or pulmonary embolism * use of warfarin * Planning to have children in the next one year
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Testosterone concentrations | 6 months | Testosterone concentrations in serum measured multiple times during the study |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hemoglobin | 6 months | blood test |
| muscle strength | 6 months | Hand-grip strength will be measured by a quantitative handgrip dynamometer in the dominant arm. Mean of three consecutive measurements will be used. |
| Lean mass | 6 months | measured by DEXA scan |
| sexual function | 6 months | Psychosexual daily questionnaire for 7 consecutive days will be used. The questionnaire covers three different domains: 1) sexual desire, enjoyment, and performance; 2) sexual activity score; and 3) mood. Sexual desire (question 1) and sexual enjoyment (question 2) will be rated on a 7-point Likert-type scale from 0 to 7, with 0 indicating none and 7 indicating very high. Sexual performance will be assessed by % full erection and satisfaction with erection (questions 5 and 6). Sexual activity (question 4) will be assessed using a checklist format. The value will be recorded as 0 (none) or 1 (any) for analysis. Higher score indicates higher activity; maximum score on this item is 12. Each mood parameter (question 3) will also be assessed on the 7-point Likert scale. |
Countries
United States
Contacts
CONTACTSandeep Dhindsa, MD
CONTACTJennifer Newman, RN
PRINCIPAL_INVESTIGATORSandeep Dhindsa, MD
St. Louis University
Outcome results
None listed